Filing Flows › Interpace Biosciences (IDXG) › Q2 2025
Interpace Biosciences (IDXG) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Interpace Biosciences (IDXG) reported revenue of $9.2M for the second quarter 2025 (Q2 2025), -23% from a year earlier and -20% from the quarter before. Operating margin was -5.1%, net loss $640K (6.9% of revenue).
Interpace Biosciences, Q2 2025: revenue $9.2M (-23% year over year), operating margin -5.1%, net loss $640K, operating cash flow $520K. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.2M | -20% | -23% |
| Operating profit | −$468K | -126% | — |
| Net earnings | −$640K | -139% | — |
| Operating cash flow | $520K | -58% | -63% |
What changed
Revenue was $9.2M in Q2 2025, down 23% year over year and down 20% from the previous quarter.
Gross margin was 57.1%, down 7.7 points from a year earlier. Operating costs exceeded revenue by $468K, an operating margin of -5.1%. Operating expenses grew 11% against a revenue fall of 23%. The fastest-growing cost line was General & admin (+24%). The quarter ended with a net loss of $640K, after a profit of $1.6M the previous quarter.
Operating cash flow was $520K (down 63% year over year). Non-cash charges added back $101K of depreciation and amortization and $9K of share-based compensation. Working capital and other items added $1.1M.
Questions
What was Interpace Biosciences' revenue in the second quarter 2025?
Interpace Biosciences (IDXG) reported revenue of $9.2M for the second quarter 2025 (Q2 2025), -23% from a year earlier and -20% from the quarter before.
Was Interpace Biosciences profitable in the second quarter 2025?
Operating loss was $468K (-5.1% of revenue) and net loss $640K.